Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Texas Oncology - Flower Mound

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Flower Mound

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Flower Mound

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Flower Mound

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Flower Mound

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Flower Mound

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Flower Mound

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: NA
USOR Number: 17079

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Flower Mound

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

4370 Medical Arts Drive, Suite 100
Flower Mound, Texas 75028
289.58 mi. away
P: (972) 537-4100

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Rockwall

CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

  • Details

ClinicalTrials.gov ID: NCT04265534
Diagnosis Type: NA
USOR Number: 19239

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Esophageal Cancer

Clinical Trial at: Texas Oncology - Rockwall

A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

  • Details

ClinicalTrials.gov ID: NCT03748134
Diagnosis Type: NA
USOR Number: 20171

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Rockwall

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Rockwall

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Rockwall

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

  • Details

ClinicalTrials.gov ID: NCT03431350
Diagnosis Type: NA
USOR Number: 19146

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Rockwall

CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Rockwall

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Rockwall

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Rockwall

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Rockwall

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Essential Thrombocythemia

Clinical Trial at: Texas Oncology - Rockwall

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Rockwall

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3144 Horizon Rd, Suite 110
Rockwall, Texas 75032
293.39 mi. away
P: (972) 771-3322

More Details View Practice Page

Pages